AZD4831 + itraconazole

**AZD4831 + itraconazole** is a combination of two pharmaceutical drugs: AZD4831 (also known as mitiperstat), a small molecule inhibitor targeting myeloperoxidase (MPO), and itraconazole, a triazole antifungal agent. - **AZD4831** is a covalent, irreversible inhibitor of myeloperoxidase (MPO), designed to decrease inflammation and improve microvascular function by inhibiting extracellular MPO activity. It shows selectivity for MPO over thyroid peroxidase (TPO) at low oral doses and is under investigation for indications related to cardiovascular disease, particularly in heart failure with preserved ejection fraction (HFpEF). - **Itraconazole** is an established broad-spectrum antifungal agent that inhibits fungal cell membrane synthesis by blocking lanosterol 14α-demethylase, an enzyme required for ergosterol production in fungi. This combination is not an established therapeutic product and may be considered for evaluation of drug-drug interaction (particularly since itraconazole is a potent CYP3A4 inhibitor and may influence metabolism and pharmacokinetics of AZD4831). There is currently no evidence of clinical use or ongoing trials specifically investigating AZD4831 + itraconazole as a fixed-dose combination for a single therapeutic indication.

Brand names

Mitiperstat

Other names

AZD4831AZD-4831AZD 4831mitiperstatitraconazole